Last checked at 20 Jul 2022 07:00
20 July 2022
Roquefort Therapeutics plc
("Roquefort Therapeutics" or the "Company")
Appointment of Joint Broker
Roquefort Therapeutics (LSE:ROQ,OTCQB:ROQAF), the Main Market listed biotech company focused on early-stage opportunities in the biotechnology sector, is pleased to announce the appointment of Hybridan LLP ("Hybridan") as its Joint Broker with immediate effect.
Stephen West, Roquefort Therapeutics Executive Chairman, commented:
"We are delighted to be working with Hybridan going forward. Hybridan has a deep understanding of the life sciences sector particularly within small caps, and their experience will be invaluable to Roquefort Therapeutics as we target further institutional investors and family offices."
-Ends-
Enquiries:
Roquefort Therapeutics plc | |
Stephen West (Chairman) | +44 (0)20 3290 9339
|
Hybridan LLP (Joint Broker) Claire Louise Noyce
Optiva Securities Limited (Joint Broker) |
+44 (0)203 764 2341 |
Christian Dennis
Buchanan (Public Relations) Ben Romney / Jamie Hooper / George Beale
| +44 (0)20 3411 1881
+44 (0)20 7466 5000
|
For further information on Roquefort Therapeutics, please visit www.roquefortplc.com and @RoquefortTherap on Twitter.
LEI: 254900P4SISIWOR9RH34
About Roquefort Therapeutics
Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF) is a Main Market listed biotech company developing products through the pre-clinical phase prior to partnering or selling to big pharma. The Company is focused on developing first in class Midkine inhibiting drugs for the treatment of cancer.
Through extensive research resulting in validation through publication in over 1,000 scientific publications, Roquefort Therapeutics has identified the potential to exploit the broad therapeutic potential of Midkine for a number of clinical indications of significant unmet needs. Roquefort Therapeutics holds an exclusive licence to the largest global IP portfolio on Midkine. The Midkine blocking drug development markets have significant global market potential (in the multi-billion dollars). Roquefort Therapeutics's pre-clinical programme is currently underway with an initial focus on cancer.